Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A therapeutic leap: how myosin inhibitors moved from cardiac interventions to skeletal muscle myopathy solutions.

The Journal of clinical investigation - 1 May 2024

Bogomolovas Julius, Chen Ju

Abstract excerpt

The myosin inhibitor mavacamten has transformed the management of obstructive hypertrophic cardiomyopathy (HCM) by targeting myosin ATPase activity to mitigate cardiac hypercontractility. This therapeutic mechanism has proven effective for patients with HCM independent of having a primary gene mutation in myosin. In this issue of the JCI, Buvoli et al. report that muscle hypercontractility is a mechanism of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzylamines
Share to Cardiomyopathy, Hypertrophic
Share to Distal Myopathies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Muscle, Skeletal

Share to Mutation

Share to Myosin Heavy Chains

Share to Myosins

Share to Uracil

Source

Open in PubMed Open full text

Identifiers

PMID: 38690729
DOI: 10.1172/JCI179958
PMCID: PMC11060725

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A therapeutic leap: how myosin inhibitors moved from cardiac interventions to skeletal muscle myopathy solutions.PMID 38690729Read ↗

Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers.Semantic proximity Read ↗

Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor.Semantic proximity Read ↗

Congenital myopathies: pathophysiological mechanisms and promising therapies.Semantic proximity Read ↗

Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibitionSemantic proximity Read ↗

Biophysical properties of human β-cardiac myosin with converter mutations that cause hypertrophic cardiomyopathySemantic proximity Read ↗

Hypertrophic cardiomyopathy: Mutations to mechanisms to therapiesSemantic proximity Read ↗

Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases.Semantic proximity Read ↗

Danicamtiv increases myosin recruitment and alters the chemomechanical cross bridge cycle in cardiac muscleSemantic proximity Read ↗

Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy.Semantic proximity Read ↗

Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibitionSemantic proximity Read ↗

The Myosin Family of Mechanoenzymes: From Mechanisms to Therapeutic Approaches.Semantic proximity Read ↗

Biophysical properties of human β-cardiac myosin with converter mutations that cause hypertrophic cardiomyopathySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.